Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM, Bashford J, Wall D, Rischin D, Parker N, Toner GC, Seymour JF, Blakey D, Haylock D, Simmons P, Francis P, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P. Prince HM, et al. Among authors: januszewicz eh. Cytotherapy. 2002;4(2):137-45. doi: 10.1080/146532402317381848. Cytotherapy. 2002. PMID: 12006209 Clinical Trial.
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Prince HM, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Wall D, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Rischin D. Prince HM, et al. Among authors: januszewicz eh. Bone Marrow Transplant. 2000 Sep;26(5):483-7. doi: 10.1038/sj.bmt.1702540. Bone Marrow Transplant. 2000. PMID: 11019836
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM, Rischin D, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Quinn M, Brettell M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P. Prince HM, et al. Among authors: januszewicz eh. Bone Marrow Transplant. 2000 Nov;26(9):955-61. doi: 10.1038/sj.bmt.1702650. Bone Marrow Transplant. 2000. PMID: 11100274 Clinical Trial.
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM, Wall D, Rischin D, Toner GC, Seymour JF, Blakey D, Haylock D, Simmons P, Wolf M, Januszewicz EH, Westerman D, Richardson G, Scarlett J, Briggs P. Prince HM, et al. Among authors: januszewicz eh. Cytotherapy. 2002;4(2):147-55. doi: 10.1080/146532402317381857. Cytotherapy. 2002. PMID: 12006210 Clinical Trial.
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Toner GC. Prince HM, et al. Among authors: januszewicz eh. Bone Marrow Transplant. 1999 Mar;23(5):427-35. doi: 10.1038/sj.bmt.1701606. Bone Marrow Transplant. 1999. PMID: 10100555 Clinical Trial.
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM, Millward MJ, Rischin D, Blakey D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Seymour JF, Brettell M, Strickland A, Zalcberg J, Richardson G, Scarlett J, Briggs P, Toner GC. Prince HM, et al. Among authors: januszewicz eh. Ann Oncol. 1999 Apr;10(4):479-81. doi: 10.1023/a:1008317205955. Ann Oncol. 1999. PMID: 10370794 Free article. Clinical Trial.
50 results